— Know what they know.
Not Investment Advice

ATXS NASDAQ

Astria Therapeutics, Inc.
1W: +1.5% 1M: +3.7% 3M: +73.6% 1Y: +43.1% 3Y: -11.6% 5Y: -8.3%
$12.58
Last traded 2025-12-31 — delisted
NASDAQ · Healthcare · Biotechnology · $718.1M mcap · 39M float · 2.72% daily turnover · Short 52% of daily vol

Balance Sheet Trends

Total Assets
$342M +34.4% ▲
5Y CAGR: +52.3%
Total Liabilities
$23M +100.0% ▲
5Y CAGR: +30.7%
Shareholders Equity
$319M +31.3% ▲
5Y CAGR: +55.0%
Cash & Investments
$328M +33.1% ▲
5Y CAGR: +55.4%
Total Debt
$5M +1527.1% ▲
5Y CAGR: +18.9%
Net Debt
-$54M +68.9% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2020FY2021FY2022FY2023FY2024
— Assets —
Cash$25M$87M$21M$176M$60M
Short-Term Investments$20M$39M$206M$71M$268M
Cash & ST Investments$45M$126M$226M$247M$328M
Net Receivables$0$0$0$0$0
Inventory$0$0$0$0$0
Other Current Assets$0$0$1M$4M$7M
Total Current Assets$46M$127M$228M$251M$335M
Property, Plant & Equip.$966K$394K$948K$363K$5M
Goodwill & Intangibles$0$0$0$0$0
Long-Term Investments$0$0$0$0$0
Other Non-Current Assets$165K$45K$2M$3M$3M
Total Non-Current Assets$1M$439K$3M$4M$8M
Total Assets$47M$128M$231M$255M$342M
— Liabilities —
Accounts Payable$2M$2M$788K$2M$4M
Short-Term Debt$0$0$0$0$0
Deferred Revenue$0$0$0$0$0
Other Current Liabilities$2M$2M$3M$4M$0
Total Current Liabilities$6M$5M$9M$12M$19M
Long-Term Debt$0$0$0$0$0
Other Non-Current Liab.$0$0$0$0$0
Total Non-Current Liabilities$397K$0$357K$0$4M
Total Liabilities$7M$5M$9M$12M$23M
— Equity —
Common Stock$4K$13K$28K$41K$57K
Retained Earnings-$261M-$456M-$508M-$581M-$675M
Accumulated OCI$0$0-$79K$0$163K
Total Stockholders Equity$41M$122M$221M$243M$319M
Total Liabilities & Equity$47M$128M$231M$255M$342M
— Key Metrics —
Total Debt$1M$365K$939K$329K$5M
Net Debt-$24M-$86M-$20M-$175M-$54M
Total Investments$20M$39M$206M$71M$268M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms